INOEL RIVERA 1812 North Mills Avenue Orlando, Florida (407)

Transcription

1 INOEL RIVERA 1812 North Mills Avenue Orlando, Florida (407) PERSONAL DATA Date of Birth: May 21, 1965 Place of Birth: Mayaguez, Puerto Rico Citizenship: U.S. Marital Status: Married to Carmen Rivera WORK HISTORY: 12/00 to Present Winter Park Urology Associates Orlando, FL APPOINTMENTS: 07/03 to present Florida State University School of Medicine-Department of Clinical Science Clinical Assistant Professor 2001 to present University of Florida Division of Urology Assistant Clinical Professor of Surgery 03/98 to 11/00 University of Florida Shands Hospital Division of Urology Assistant Professor 11/97 to 03/98 University of Florida Shands Hospital Division of Urology Clinical Assistant Professor 06/97 to 10/97 University of Florida Shands Hospital

2 Division of Urology Acting Chief of Urologic Oncology 07/96 to 06/97 University of Florida Shands Hospital Division of Urology Adjunct Assistant Professor 07/96 to 09/99 Veterans Administration Hospital Gainesville, FL Attending Urologist EDUCATION AND HONORS 07/95 to 06/96 University of Florida Shands Hospital Division of Urologic Oncology Zev Wajsman, M.D. Urologic Oncology Fellowship University of Florida Pfizer Award for Excellence in Teaching 07/92 to 06/95 University of Puerto Rico School of Medicine Rio Piedras, Puerto Rico Urology Section 07/90 to 06/92 University of Puerto Rico, School of Medicine Rio Piedras, Puerto Rico (Accredited by the Liaison Committee of Medical Education) Completed Straight Surgery Internship PGY-1, June 1991 Completed Straight Surgery, PGY-2, June /86 to 06/90 University of Puerto Rico, School of Medicine Rio Piedras, Puerto Rico (Accredited by the Liaison Committee of Medical Education) M.D. - June University of Puerto Rico, Mayaguez Campus Mayaguez, Puerto Rico

3 B.S. in Natural Sciences 1987 Magna Cum Laude UPR Dean s Honor List Certified Space Shuttle Medical Support Team June 1996 Pfizer Scholars in Urology Award LICENSURES NBME Part I Approved in September 1989 NBME Part II Approved in April 1990 NBME Part III Approved in March 1991 Puerto Rico Board of Medical Examination Approved in April 1989 The American Board of Urology Part I Approved on June 1, 1995 Part II Approved in February 1998 State of Florida Medical License #69538 Approved in October 1995 Puerto Rico Medical License Approved August 1995 Fellow of American college of Surgeons Effective October 2000 RESEARCH EXPERIENCE 2005-Present 2005-Present Sub-Investigator: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of XXXX for the Prevention of Prostate Cancer in Men with High Grade Prostate Intraepithelial Neoplasia. Sub-Investigator: A Multicenter, 2 Week, Double-Blind Study of XXXX 60mg QD Modified Release Capsules and Placebo Given Once Daily In The Morning or In The Evening in Patients With Overactive Bladder Present Sub-Investigator: A Placebo-Controlled, Double- Blind, Randomized, Parallel Study of the

4 Withdrawal Effects of Chronic Daily and As Needed Dosing with Study Drug in the Treatment of Premature Ejaculation. Sub-Investigator: Prospective, Observational Registry and Patient Survey of the Management of Men with Symptomatic Benign Prostatic Hyperplasia. Sub-Investigator: An Open-Label, Multicenter Study To Assess the Efficacy and Safety of Oral Administration of 5 and 10mg Study Drug in Patients Who Wish to Switch from Detrol LA for the Treatment of Overactive Bladder Symptoms. Sub-Investigator: A Study to Compare the Safety and Efficacy of Once Daily Study Drug in the Treatment of Complicated Urinary Tract Infection And Acute Pyelonephritis. Sub-Investigator: A Double-Blind, Randomized, Placebo-Controlled Trial of Elmiron For The Treatment of Chronic, Non-Bacterial Prostatitis. Sub-Investigator: A Randomized, Double-Blind, Crossover Study to Evaluate the Duration of Erection following Study Drug 10mg Administration For 4 Weeks in a Fixed-Dose Regimen Compared to Placebo in Males with ED. Sub-Investigator: A Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Study of Study Drug for the Prevention of Bone Fractures in Men with Prostate Cancer on Androgen Deprivation Therapy. Sub-Investigator: Study of XXXX in Women of Different Demographic Characteristics and Co-morbidities With Stress Urinary Incontinence: Evaluation of Efficacy and Safety REALISE: Real Life Safety and Efficacy of Levitra Sub-Investigator: A Double-Blind, Placebo-Controlled Study of Frequency and Urgency Using Study Drug 0.5mg Twice Daily For 12 Weeks Followed by a 6-Month Open

5 Label Treatment Phase in Patients with Overactive Bladder Sub-Investigator: A Multicenter, Open Label, Flexible Dose Study to Investigate the Use Patterns of Viagra (sildenafil citrate) And The Ability of Investigators To Further Optimize Subject Satisfaction With Viagra Through Customized Instruction Sub-Investigator: An Open-Label Study to Evaluate the Efficacy and Safety of Study Drug Administered On Demand to Men of Various Populations with Erectile Dysfunction Sub-Investigator: A Phase 3, Parallel Group, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial to Investigate the Efficacy, Tolerability and Safety of Study Drug Sustained Release in Subjects with Overactive Bladder Syndrome Sub-Investigator: A Double-Blind, Placebo-Controlled Randomized US/Latin America Study to Evaluate the Effect of Study Drug Prolonged Release on Nocturia In Patients with Symptoms of Overactive Bladder (OAB) 2003-Present Sub-Investigator: A Double-Blind, Placebo-Controlled Parallel Group Study of the Efficacy and Safety of Study Drug 0.5mg Administered Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer Sub-Investigator: A Phase 3B, Multi-Center, Double- Blind, Randomized, Placebo-Controlled, Parallel Group Study of Study Drug in Subjects with Overactive Bladder Principal Investigator: An Open-label Trial on the Effect of IV Study Drug 4mg on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients with Bone Metastasis Principal Investigator: A Randomized, Placebo- Controlled, Serum-Level Targeted Study Investigating the Safety and Pharmacokinetics of Orally Administered Study Drug in Patients with Various Malignancies Principal Investigator: A Randomized, Double-Blind, Parallel Group, Multi-center, Study to Investigate the

6 Time to Onset of Action of 20mg Study Drug Compared to Placebo in Males with Erectile Dysfunction Sub-Investigator: A Multicenter, Phase IIB, Four Arm, Dose Finding, Randomized, Placebo-Controlled Study to Determine the Long Term Prostate Cancer Chemoprevention Efficacy and Safety of 20mg, 40mg & 60mg Daily of Study Drug in Men with High Grade Prostate Intraepithelial Neoplasia (PIN) Sub-Investigator: A Phase III, Double-Blind, Randomized, Parallel Study Evaluating the Safety and Efficacy of Study Drug in the Treatment of Male Erectile Dysfunction Sub-Investigator: Double-Blind, Placebo-Controlled Study of Sustained Release Study Drug in Subjects with Symptoms of Overactive Bladder of Urgency, Frequency and Urinary Incontinence Sub-Investigator: An Investigation Of The NMP22 Point of Care (POC) Device As An Aid In The Monitoring of Bladder Cancer Patients Sub-Investigator: An Investigation Of The NMP22 Point of Care (POC) Device As An Aid In The Screening of Patients At Risk For Bladder Cancer Principal Investigator: Extended Safety and Efficacy Study of Duros Leuprolide Implant in Patients with Prostate Cancer Principal Investigator: Safety and Efficacy Study of Duros Leuprolide Implantable Therapeutic System in Patients with Prostate Cancer Principal Investigator-Feasibility, Functionality and Dose Ranging Study of Duros Leuprolide Implantable Therapeutic System in Patients with Advanced Prostate Cancer Co-Principal Investigator-Combined Intravesical Immunotherapy using BCG and Recombinant Interferon for Treatment of Recurrent Superficial Transitional Cell Carcinoma of the Bladder. Principal Investigator-Zev Wajsman, M.D Co-Principal Investigator-Phase III Randomized Study of a Single Adjuctive Instillation of Intravesical AD

7 32 versus No Adjunctive Therapy Immediately Following Transurethral Resection in Patients with Multiple Superficial Bladder tumors Principal Investigator Zev Wajsman, M.D Co-Principal Investigator-Phase II Intravesical AD 32 in Patients with Transitional Cell Carcinoma. Principal Investigator Zev Wajsman, M.D Co-Principal Investigator-Phase II Intravesical AD 32 in Patients with Carcinoma In Situ of the Bladder Who have Failed or Have Recurrence Following Treatment with BCG. Principal Investigator Zev Wajsman, M.D Co-Principal Investigator-Randomized Prospective Study Comparing Radical Prostatectomy Alone versus Radical Prostatectomy Preceded by Androgen Blockade with Clinical DB2 Prostate Cancer. Principal Investigator Zev Wajsman, M.D Co-Principal Investigator-RTOG 95:06: Phase I/II Trial of Transurethral Surgery Plus Induction of Chemoradiotherapy Followed Either By Selective Bladder Preservation of Radical Cystectomy as Determined by Initial Response and Operability in Patients with Muscle-invading Bladder Cancer. Principal Investigator Zev Wajsman, M.D Co-Principal Investigator-A Randomized, Comparative Trial of Casodex versus Flutamide Used In Combination with Medical Castration in Patients With Untreated Metastatic Prostate Cancer. Principal Investigator Zev Wajsman, M.D Microsurgery in the Musca domestica eye: Research in mechanism of action of the pseudopupil in the Musca domestica. Proctor: Michael Wilcox, Ph.D. in Biophysics PRESENTATIONS 1999 Treatment of Invasive Bladder Cancer there is a place for radical surgery in the year 2000? Florida Urological Society.

8 1999 New Advances in Radical Bladder Surgery movie submitted for American Urological Association in the year Radioactive Seed Implantation for the Treatment of Prostate Cancer. Puerto Rico Urological Society Radioactive Seed Implantation for the Treatment of Prostate Cancer. Selected topics in Urology Treatment for Localized Prostate Cancer. Radiation Oncology Clinical Research Seminar. April 1997 September 1996 March 1995 February 1994 The Impact Of Interinstitution Pathologic Review on the Management of Patients With Urologic Malignancies, American Urological Association Meeting. Acute Normovolemic Hemodilution: A Cost Efficient Alternative to Autologous Blood in Urologic Surgery. Guest speaker at the Puerto Rico Urological Association Annual Meeting. Treatment of Metastatic Squamous Cell Carcinoma of the Penis to the Inguinal Lymph Nodes at the Southeastern Section of the American Urologic Association. Tensor Fascia Lata Myocutaneous Flap in Inguinal Lymphadenectomy For Metastatic Carcinoma of Penis Presented at the Second Annual Florida Resident Meeting February ABSTRACTS: 2000 Bladder Sparing Treatment of Invasive Bladder Cancer. Inoel Rivera, MD and Zev Wajsman Accepted: Journal of Moffitt Cancer Center 2000 Pending The Outcome of Patients with Carcinoma of the Prostate treated with Adjuvant and Salvage Radiation after Radical Prostatectomy. Endre Neulander, Inoel Rivera-Ramirez, Robert Zlotecki and Zev Wajsman. Pending

9 2000 Pending The effect of the follow-up Cytoscopy interval on the Outcome of patients with Bladder tumors receiving Adjuvant Intravesical Instillation. Endre Neulander, Inoel Rivera-Ramirez, Lorenzo Luciani, Nadeem Dahani and Zev Wajsman. Pending. March 2000 November 1999 March 1999 June 1998 April 1997 March 1997 March 1997 The Outcome after Radical Prostatectomy in Patients with Preoperative PSA above 15 ng/ml. Endre Neulander, Inoel Rivera-Ramirez, Gerard Curtis, Nadeem Dahani and Zev Wajsman. Submitted to the SE Section of the AUA, March 2000 The Simple Cystectomy in High Risk Patients Requiring Urinary Diversion. Endre Z. Neulander, Inoel Rivera-Ramirez and Zev Wajsman. Accepted at the International Bladder Symposium, Washington, D.C., November 4-7. Combined Intravescical Immunotherapy using BCG and Recombinant Interferon for Treatment of Refractory Carcinoma In Situ (CIS). Curtis G., Wright N., Inoel Rivera-Ramirez and Zev Wajsman. A Phase I/II Dose Ranging Study of Duros (Leuprolide) Implantable Therapeutic System in Patients with Advanced Prostate Cancer. Jackson, R., Flower, Jackson, MS,; James E. Gottesman, Seattle, WA; Stephan F. Bardot, New Orleans, LA; C. Frederick Reid, Winston-Salem, NC; Gerald L. Andriole, St. Louis, MO; Peter H. Bernhard, Minneapolis, MN; Inoel Rivera-Ramirez, Gainesville, FL; John A. Libertino, Burlington, MA; and Mark S. Soloway, Miami, FL. The Impact of Interinstitution Pathologic Review of Management of Patients With Urologic Malignancies. The Bladder Tumor Antigen Test vs. Voided Urine Cytology for Detecting Recurrent Bladder Cancer. Acute Normovolemic Hemodilution: A Cost Efficient Alternative to Autologous Blood in Urologic Surgery. March 1995 Treatment of Metastic Squamous Cell Carcinoma of

10 The Penis to the Inguinal Lymph Nodes at the Southeastern Section of the American Urologic Association PUBLICATIONS Inoel Rivera-Ramirez, Zev Wajsman: Bladder- Sparing Treatment of Invasive Bladder Cancer. CANCER CONTROL, Journal of the Moffitt Cancer Center; Vol. 7, , Endre Z. Neulander, Inoel Rivera-Ramirez, et al: Radical Prostatectomy in Patients with High Preoperative PSA. UROLOGY (in press) January 1998 Cristoforo L. Cama, Inoel Rivera-Ramirez, Zev Wajsman; Male Genitalia s Malignancy, Jacksonville Medicine. CME credits 2001 Inoel Rivera, Zev Wajsman: Cancer of the Kidney and Ureter. Surgical Oncology: Contemporary Principles & Practice. 17A pp December 1997 William M. Murphy, Inoel Rivera-Ramirez, Camilo A. Medina, Nancy J. Wright and Zev Wajsman: The Bladder Tumor Antigen (BTA) Test Compared to Voided Urine Cytology in the Detection of Bladder Neoplasms. The Journal of Urology; Vol. 158, SOCIETIES AND COMMITTEES Florida Medical Association 2000 Puerto Rico Urological Association 1998 American Urological Association 1997 Member of the Committee for the Revision of the MCAT, 1988 Beta-Beta-Beta Honor Society, Florida Urological Society 1998 O.R. Committee with Shands Hospital at the University of Florida Collaborator State of Florida Prostate Cancer Task Force Peer reviewer for the Journal of Urology Updated 2/2005